Albumin News and Research

RSS

JDRF-funded study aims to find new types of diagnostic markers for diabetic kidney disease

In an effort to pinpoint the earliest signs of diabetic kidney disease, researchers at University of California, San Diego School of Medicine are leading a multi-institutional international effort dedicated to finding a new breed of disease indicators.

23 Oct 2015

Certain laboratory results can help to predict survival in patients with brain metastases

A new MedUni Vienna study conducted in the Comprehensive Cancer Centre (CCC) Vienna shows that certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.

26 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

NUS researchers develop new technique to observe nano-bio interactions

Researchers at the National University of Singapore have developed a technique to observe, in real time, how individual blood components interact and modify advanced nanoparticle therapeutics.

16 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA.

2 Sep 2015

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

When it comes to treating high blood pressure, not all anti-hypertensive medications are equal, and results of the ATTEMPT-CVD trial suggest that telmisartan, an angiotensin II receptor blocker (ARB) might have benefits over non-ARB treatment.

31 Aug 2015

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Liver transplantation is currently the only established treatment for patients with end stage liver failure. However, this treatment is limited by the shortage of donors and the conditional integrity and suitability of the available organs. Transplanting donor hepatocytes (liver cells) into the liver as an alternative to liver transplantation also has drawbacks as the rate of survival of primary hepatocytes is limited and often severe complications can result from the transplantation procedure.

27 Aug 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

No single genetic strain associated with the worst cases of C. difficile infections

No single genetic strain of the widespread Clostridium difficile (C. difficile) bacteria appears to be any more harmful than other strains, according to new research published online today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

21 Aug 2015

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors.

5 Aug 2015

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.

31 Jul 2015

UC San Diego researchers identify pivotal player in diabetic kidney disease

Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease.

23 Jul 2015

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio Pharmaceuticals, Inc. today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion in the treatment of osteoarthritis in the knee.

9 Jun 2015

Green Cross Biotherapeutics starts construction on new biopharmaceutical facility in Montreal

This is with great pride that Green Cross Biotherapeutics Inc. kicked off construction today on its biopharmaceutical facility that will be located on the Montreal Technoparc's Saint-Laurent Campus. The CA$315 million project represents one of the largest green field investment projects in Canada in the biopharmaceutical industry, giving place to the construction of the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Canada.

2 Jun 2015

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015.

1 Jun 2015

Measuring kidney function and damage may help predict people at risk for heart disease

Simple measures of kidney function and damage may be just as good at predicting who is at risk for heart failure and death from heart attack and stroke as traditional tests of cholesterol levels and blood pressure, new Johns Hopkins Bloomberg School of Public Health-led research suggests.

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

Aflatoxin exposure associated with increased risk of gallbladder cancer

In a small study in Chile that included patients with gallbladder cancer, exposure to aflatoxin (a toxin produced by mold) was associated with an increased risk of gallbladder cancer, according to a study in the May 26 issue of JAMA.

27 May 2015

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis.

23 Apr 2015